Srishti Khurana

Drug developers heavily rely on a number of broadcasting channels, which include direct to consumer (DTC) advertisements, product websites and conferences, to promote their proprietary drugs. The...

The introduction of insulin therapy in the 1920s, for the treatment of diabetes, marked the beginning of the therapeutic use of peptides. Presently, peptide-based therapeutics represent a prominent...

Several big pharmaceutical players have carried out multiple biopharmaceuticals focused initiatives, including acquisitions, facility establishments, joint ventures, partnerships / collaborations, and...

Rising complexities related to handling and administration of novel / advanced therapeutic options, have caused many device developers to outsource certain aspects of their businesses to contract...

The current biopharmaceuticals market is characterized by high quality standards and a rapidly growing demand for novel and effective treatment options. It is, therefore, a technically challenging...

Over the years, China’s biopharmaceutical segment has grown to represent a significant share of the overall pharmaceutical industry. Innovation trends, enhanced regulations, and lucrative funding from...

Majority share (53%) of the biopharmaceutical contract manufacturing capacity in China is primarily driven by mid-sized companies. This can be attributed to relatively higher number of mid-sized...

Currently, over 35 CMOs / CDMOs in China claim to offer manufacturing services for biopharmaceuticals. Majority of these (55%) are mid-sized companies (51-500 employees), followed by 24% very large...

The number and geographical distribution of clinical trials are important indicators of both the therapeutic viability and future potential of innovative pharmacological interventions. It is obvious...

The first successful use of prefilled syringes can be traced back to early 1980s when Sanofi and Rhone Poulenc-Rorer (Sanofi-Aventis) introduced syringes as drug delivery devices for heparins, in...

RNA interference is a post transcriptional gene silencing process that is believed to have the potential to treat undruggable diseases. Unlike other drugs, which target a disease at the protein level...

China is a giant market buoyed with international scientific and technical capabilities in biopharmaceuticals. However, various challenges associated with the development process of biologics, such as...

Gene editing technologies allow the researchers to change the genetic material of an organism. This change can be due to any addition, deletion or alteration at specific location in the genome...

An informed capability assessment of different geographies, such as North America, Europe and Asia Pacific, is based on a variety of relevant parameters, such as number of CMOs, number of clinical...

As therapeutic agents, oligonucleotides are known to be associated with several unique features, such as high selectivity and potency (similar to biologics), and differentiated pharmacology, which...